Roman A Zubarev
Karolinska Institutet, Sweden
Posters & Accepted Abstracts: J Proteomics Bioinform
Mass-spectrometry based proteomics is widely used to profile proteome changes in cancer cells in response to different anticancer treatments. The proteome changes are expected to follow one of the established death pathways. Until 2008, three such mechanisms have been widely recognized. In 2012, the Nomenclature Committee on Cell Death (NCCD) has listed 13 distinct mechanisms of cellular death. However, in the 2015 NCCD report this classification has effectively been disavowed, because new research has shown that programmed death pathways previously believed to be unidirected are actually reversible. To differentiate between different modes of cell death, we mapped the proteome changes occurring in three attached cell lines treated with 50 different anticancer agents. Upon 24 hours incubation at a dose at which 50% cells are tested as dead, the stillattached cells and the floating cells were separately collected with the floating population showing the majority of dead cells while the attached cells consist of preferentially living cells. Proteome comparison of the surviving and dying cells with the untreated cells reveals the specific mechanisms of drug action as well as the pathways of death and survival that are common for all tested cell lines and drugs. Thus created proteomics atlas of cancer cell death and survival will serve as a reference in fundamental studies as well as in drug development.
Email: Roman.Zubarev@ki.se
